Novo Nordisk A/S (NYSE:NVO) Receives Daily Media Sentiment Score of 0.17
News stories about Novo Nordisk A/S (NYSE:NVO) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novo Nordisk A/S earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.4556757104102 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Brokerages Anticipate Novo Nordisk A/S (NYSE:NVO) to Announce $0.56 Earnings Per Share (americanbankingnews.com)
- Comparing Novo Nordisk A/S (NVO) & Taro Pharmaceutical Industries (TARO) (americanbankingnews.com)
- Novo Nordisk H1 Profit Rises; Raises FY Operating Profit Growth Outlook (nasdaq.com)
- Why Earnings Season Could Be Great for Novo Nordisk (NVO) (finance.yahoo.com)
- Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade (finance.yahoo.com)
Shares of Novo Nordisk A/S (NVO) traded up 8.31% during mid-day trading on Wednesday, hitting $44.57. The company had a trading volume of 3,637,672 shares. The firm has a 50-day moving average price of $42.86 and a 200 day moving average price of $38.45. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $50.30. The firm has a market capitalization of $111.24 billion, a P/E ratio of 18.33 and a beta of 0.63.
A number of analysts have recently commented on NVO shares. TheStreet upgraded Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a research report on Wednesday, June 21st. Finally, BidaskClub upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, June 15th. Five equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $53.00.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.